相关临床试验
5
5 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
20.0%
尚未招募
4
80.0%
暂无批准数据
- Twenty-one UWA researchers received $2.1 million in WA Near-Miss Awards bridging funding for projects spanning paediatric cancer immunotherapy, respiratory infections, and cardiovascular diagnostics. - Three UWA-led projects secured over $4 million in NHMRC Investigator Grants, including genetic research into neuromuscular diseases and recurrent miscarriages led by Professor Gina Ravenscroft. - Dr Omar Elaskalani and Dr Anthony Buzzai received grants to advance immunotherapy and dissect cancer-immune interactions in childhood cancers, addressing critical unmet needs in paediatric oncology. - Dr Emma Haynes will co-design a health communication model with First Nations communities to improve informed decision-making and reduce communication failures in healthcare.
- Professor Gina Ravenscroft, an internationally recognised leader in rare neuromuscular disease genomics, has been appointed the inaugural Dr Patricia Kailis Chair in Rare Diseases at The University of Western Australia. - The endowed chair is jointly funded by the Harry Perkins Institute of Medical Research, the Stan Perron Charitable Foundation, and UWA, representing the largest per-capita commitment to rare diseases globally. - The position forms part of the WA Rare Care Comprehensive Centre and aims to accelerate genetic diagnosis and the development of personalised treatments for rare diseases. - Professor Ravenscroft highlights recent advances such as personalised CRISPR-based therapies as evidence of a shift from diagnosis toward targeted, personalised medicines.
- A study of nearly 4,800 adults aged 45–69 found that higher visceral fat levels are associated with faster biological ageing in both men and women, independent of overall body weight. - In women, greater visceral fat was also linked to shorter telomere length, a key marker of cellular ageing, even after adjusting for BMI, waist circumference, and lifestyle factors. - Researchers note that visceral fat secretes pro-inflammatory proteins that contribute to systemic inflammation and metabolic stress, and can be measured via routine bone-density imaging. - The findings underscore the importance of targeting deep abdominal fat in strategies aimed at promoting healthier ageing.
- OncoRes Medical closed an A$27 million funding round led by Brandon Capital Partners to advance its Elora Quantitative Micro-Elastography imaging system for breast-conserving surgery. - The Perth-based company has initiated an Australian clinical trial across six hospitals recruiting over 110 breast cancer patients, marking the first interventional use of the Elora device. - Elora provides real-time tumor assessment during surgery by creating micro-scale 3D maps of tissue properties to help surgeons identify residual cancer and potentially reduce repeat operations. - The technology addresses a significant clinical need, as approximately one in five women undergoing breast-conserving surgery require repeat operations to remove residual tumor tissue.
- The phase 3 DREAM3R trial demonstrated favorable trends for durvalumab plus chemotherapy in advanced pleural mesothelioma, with median overall survival of 21 months versus 18 months for chemotherapy alone. - Despite showing a 58% objective response rate compared to 35% with chemotherapy alone, slow patient accrual and evolving standard-of-care practices led to early trial termination and inconclusive results. - The study's design was complicated by the 2021 CheckMate 743 results establishing nivolumab plus ipilimumab as the new standard of care, making chemotherapy alone no longer appropriate as a control arm. - Researchers suggest the high tumor response rates observed with durvalumab plus chemotherapy warrant future investigation in the neoadjuvant setting.
- The RESTORE trial demonstrates that cognitive functional therapy (CFT) produces clinically important reductions in chronic low back pain and activity limitations that persist for three years. - CFT, delivered through seven sessions by specially trained physiotherapists, significantly outperformed usual care in reducing both pain intensity and physical activity limitations. - This represents the first large, high-quality study investigating long-term CFT outcomes, offering potential to markedly reduce the global burden of chronic back pain. - The biopsychosocial approach addresses physical, psychological and social factors while empowering patients with self-management skills and confidence to move.
